A B.C.-based grower is the first Canadian company with approval from the U.S. Drug Enforcement Administration to export a medical cannabis product south of the border for use in a clinical trial. Several states have legalized cannabis for medical or recreational use, but marijuana remains an illegal Schedule 1 drug under U.S. federal law. Tilray will be exporting capsules containing active cannabis ingredients for a clinical trial into treatment for essential tremor. The clinical trial on 16 adult participants diagnosed with essential tremor is expected to begin in 2019. Tilray will not have any proprietary claim to the results and it is largely an unfunded study, Nahab said.

Source: CBC News September 18, 2018 15:44 UTC